Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials

Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials

Source: 
Xconomy
snippet: 

Neurological drug developer Aptinyx has stopped enrollment in three of the four mid-stage trials it is conducting due to impacts from the coronavirus pandemic.

The Evanston, IL-based company disclosed the decision Monday in its report of fourth quarter and full year 2019 financial results.